We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NIH DECLINES TO ISSUE 'MARCH-IN' ORDERS ON PFIZER'S XALATAN
NIH DECLINES TO ISSUE 'MARCH-IN' ORDERS ON PFIZER'S XALATAN
September 27, 2004
Following a similar decision in August, the National Institutes of Health (NIH) has rejected a petition by an advocacy group seeking to break patents on Pfizer’s glaucoma drug Xalatan so that licenses could be issued for generic competition.